Advanced Systemic Mastocytosis Treatment: A Complete Guide

How to Live Well With Advanced Systemic Mastocytosis

Explore how to manage life with advanced systemic mastocytosis.
How to Live Well With Advanced Systemic Mastocytosis

Advanced systemic mastocytosis (advSM) is a rare and serious form of systemic mastocytosis, a blood disorder that involves the overproduction of mast cells. Mast cells are a type of white blood cell normally involved in allergic reactions and immune defense that release histamine and other chemicals to help fight infections and respond to allergens.

In a person with systemic mastocytosis, these cells grow uncontrollably and accumulate in various tissues, including the skin, liver, spleen, bone marrow, and gastrointestinal tract.

Systemic mastocytosis is often caused by changes (mutations) in a gene called KIT, which is responsible for regulating the growth and function of mast cells. This flaw in the KIT gene is usually not inherited.

Most people with systemic mastocytosis have a milder form of the disease, which can be managed with medications and lifestyle changes. But advanced systemic mastocytosis requires more intensive interventions, has a much poorer prognosis, and can cause severe organ damage or an aggressive form of leukemia.

If you or someone you know is living with this condition, it is essential to work with your healthcare team to find the best treatment approach.

Tyrosine Kinase Inhibitors and chemotherapy
Newer therapies for advanced systemic mastocytosis reduce the number of mast cells and potentially restore compromised organ function.Adobe Stock (2)

Types of Advanced Systemic Mastocytosis

There are three types of advanced systemic mastocytosis.

SM With Associated Hematologic Neoplasm (SM-AHN)

SM-AHN refers to systemic mastocytosis that occurs alongside another hematologic (blood-related) disorder, such as myelodysplastic syndrome, myeloproliferative neoplasm, or acute myeloid leukemia. In this form, patients have both the characteristic mast cell proliferation of systemic mastocytosis and a secondary blood disorder.

Aggressive Systemic Mastocytosis (ASM)

Aggressive systemic mastocytosis is a more severe form of systemic mastocytosis in which mast cells infiltrate organs such as the liver, spleen, bone marrow, lymph nodes, and intestines. This variant of ASM can cause significant organ dysfunction and failure, and patients often experience more rapid disease progression. In some cases, aggressive systemic mastocytosis can develop into mast cell leukemia, a very aggressive form of systemic mastocytosis.

Mast Cell Leukemia (MCL)

Mast cell leukemia is one of the rarest and most aggressive forms of systemic mastocytosis. In MCL, a significant number of immature mast cells are found in the bone marrow and circulating blood. It may happen in people with aggressive systemic mastocytosis who have a buildup of mast cells.

Treatment Goals

The goal of treatment in people with advanced systemic mastocytosis is to control symptoms, mitigate organ damage, improve quality of life, and extend a person’s life.

“Higher-intensity therapies are needed, because we’re not only trying to manage symptoms, we’re actually trying to use therapies that kill off the mast cells and potentially restore organ function,” says Jason Gotlib, MD, a professor of hematology at Stanford University School of Medicine and a hematologist at Stanford Health Care, both in Stanford, California.

The only cure for advanced systemic mastocytosis is hematopoietic stem cell transplantation, sometimes referred to as a bone marrow transplant.

 It’s recommended that people diagnosed with advanced systemic mastocytosis be evaluated early to find out if they are eligible for transplantation.

Before starting or changing any treatment plan, it is crucial to consult with your healthcare provider. Advanced systemic mastocytosis is a complex condition, and treatment approaches vary depending on the subtype and the severity of the disease.

Medications

Treatment for advanced systemic mastocytosis depends on the subtype as well as the specific symptoms and disease progression of each person.

Tyrosine Kinase Inhibitors (TKIs)

In advanced forms of systemic mastocytosis, such as aggressive systemic mastocytosis (ASM) and mast cell leukemia (MCL), drugs known as tyrosine kinase inhibitors (TKIs) may be prescribed.

These drugs work by inhibiting the tyrosine kinase activity of the KIT protein.

  • Avapritinib (Ayvakit) is the primary TKI used, because it specifically targets the KIT D816V mutation, which is found in most people with advanced systemic mastocytosis.

  • Midostaurin (Rydapt), a less specific multikinase TKI, has been shown to improve survival and reduce symptoms in patients with aggressive systemic mastocytosis.

  • Imatinib mesylate (Gleevec) may be helpful for types of systemic mastocytosis with certain non-D816V KIT mutations.

Immunomodulators

Interferon α is a type of immunomodulator and a type of cytokine protein. It increases the function of the body’s immune system, and although it’s rarely used in advanced systemic mastocytosis, it may reduce symptoms related to mast cell activation and improve some symptoms related to mast cell overaccumulation, especially in people who aren’t candidates for other therapies.

Chemotherapy

In people with aggressive systemic mastocytosis or mast cell leukemia, chemotherapy may be necessary. This type of treatment can work through various mechanisms of action, such as damaging the DNA (deoxyribonucleic acid) or RNA (ribonucleic acid) in cancer cells and interfering with their ability to grow or multiply.

The drug cladribine, which belongs to a group of chemotherapy medicines called antimetabolites, is a commonly used option. It interferes with the growth of cancer cells and reduces mast cell activation symptoms. This intravenous infusion is used in people who need a rapid reduction of the mast cell burden, though it is not specifically approved for people with advanced systemic mastocytosis.

Symptom Management

In addition to medications used to treat the underlying disease, doctors may prescribe a range of medications to help manage symptoms of advanced systemic mastocytosis, including:

  • Antihistamines to relieve itching, hives, and gastrointestinal discomfort caused by the release of histamine
  • Leukotriene modifiers, such as montelukast, to control skin symptoms
  • Bisphosphonates to treat osteoporosis
  • Corticosteroids to reduce inflammation and control symptoms, especially in more severe cases
  • Pain medication, both over-the-counter and prescription, to treat pain
  • Proton pump inhibitors to help with peptic ulcer disease that can occur with systemic mastocytosis
  • Cromolyn sodium to relieve abdominal pain and diarrhea
  • Epinephrine to treat anaphylaxis
  • Monoclonal antibodies, particularly omalizumab, to treat recurrent anaphylaxis or anaphylaxis that doesn’t respond to other treatments

Stem Cell Transplantation

Depending on a person’s age and how they’ve responded to treatments, stem cell transplantation may be an option. Less invasive than surgery, the procedure is more like a blood transfusion.

Hematopoietic stem cell transplantation (ΗCT) is a medical procedure that involves replacing damaged or diseased blood-forming cells in the body with healthy ones. The treatment is typically used to treat blood disorders and certain blood cancers.

The procedure is the only cure for people with advanced systemic mastocytosis, and it’s usually only performed in selected younger patients.

The type of stem cell transplant used in advanced systemic mastocytosis is called allogeneic hematopoietic stem cell transplantation. In this type of HCT, the blood-forming cells come from another person (a donor) rather than from the patient themselves (a so-called autologous stem cell transplant). The donor is usually someone who is a close match genetically, like a family member, although an unrelated donor from a registry can sometimes be used.

Allogeneic HCT comes with risks. The body needs time to adjust to the donor cells, and sometimes the immune system attacks the new cells, called graft-versus-host disease (GVHD), which is a serious side effect.

This procedure is typically only considered for people with severe, advanced cases, and it’s usually only tried after other treatment options haven’t worked.

Surgery for Advanced Systemic Mastocytosis

Surgery is not a treatment option for advanced systemic mastocytosis, though in some cases, surgery may be necessary to manage complications from organ damage caused by the disorder.

For example, if the spleen becomes severely enlarged (splenomegaly) due to the infiltration of mast cells, a splenectomy (removal of the spleen) may be recommended.

How to Find the Best Provider

“Because advanced systemic mastocytosis is so uncommon, it’s important to find a physician who is comfortable managing this condition,” says Nikolai Podoltsev, MD, PhD, an associate professor of internal medicine (hematology) and the clinical director of malignant hematology at Yale School of Medicine in New Haven, Connecticut.

“Find a Center of Excellence and a physician who is interested in management of these diseases,” he says.

The Mast Cell Disease Society offers an online tool to help you find a Center of Excellence in your area.

Clinical trials for blood cancers may be another way to have access to the best care and medications available.

Lifestyle Changes for Managing Advanced Systemic Mastocytosis

Avoid these triggers in your day-to-day life to make living with advanced systemic mastocytosis easier.
Lifestyle Changes for Managing Advanced Systemic Mastocytosis

Lifestyle Changes to Manage Advanced Systemic Mastocytosis

Medications are essential in managing advanced systemic mastocytosis. But lifestyle changes can contribute to symptom management and improve overall quality of life.

Avoid Triggers

Mast cell activation can be triggered by various factors, such as certain foods, environmental allergens, and stress. Identifying and avoiding these triggers can help reduce the frequency of symptoms.

But that’s a strategy that’s more effective in people whose systemic mastocytosis hasn’t become advanced disease, says Dr. Podoltsev.

“In advanced systemic mastocytosis, the triggers are less important, because there are so many mast cells that they begin causing aggressive systemic symptoms and organ damage,” he says.

When that’s happening, an allergic reaction isn’t what’s triggering the most severe symptoms, he explains.

Stress Management

Stress can exacerbate symptoms in people with advanced systemic mastocytosis.

“If you want to try practices like yoga, meditation, or acupuncture, they may help with quality of life, provided your healthcare team approves,” says Dr. Gotlib.

Mental Health Considerations

Advanced systemic mastocytosis can be emotionally challenging, especially when symptoms like pain or fatigue are persistent.

Depression or other mood disorders aren’t uncommon with advanced systemic mastocytosis. They have what is basically a rare orphan hematologic disease that’s very uncommon, and it’s not easy to find specialists,” says Gotlib.

This can be a chronic, debilitating, painful condition with very significant impacts on quality of life, he says.

“People often have no appetite, lose weight, and have fatigue along with all the other complications that can come with the disease,” says Gotlib.

People with advanced systemic mastocytosis should discuss any pain or mood issues with their healthcare team so that they can get the treatment they need to have the best quality of life possible, says Gotlib.

Support groups, both in-person and online, provide a sense of community and can be a valuable resource for coping strategies, emotional support, and information about new treatments. The Leukemia and Lymphoma Society has an online tool to locate support groups in your community.

The Takeaway

  • Advanced systemic mastocytosis is a rare and serious condition in which mast cells grow uncontrollably and cause damage to various organs.
  • Treatment goals for advanced systemic mastocytosis focus on managing symptoms, preventing organ damage, and improving quality of life, with hematopoietic cell transplantation being the only potential cure.
  • A Center of Excellence and a provider familiar with advanced systemic mastocytosis are important to ensure you receive the best possible treatment.
conor-steuer-bio

Conor Steuer, MD

Medical Reviewer

Conor E. Steuer, MD, is medical oncologist specializing in the care of aerodigestive cancers, mesothelioma, and thymic malignancies and an assistant professor in the department of hematology and medical oncology at the Emory University School of Medicine in Atlanta. He joined the clinical staff at Emory's Winship Cancer Institute as a practicing physician in July 2015. He currently serves as chair of the Lung and Aerodigestive Malignancies Working Group and is a member of the Discovery and Developmental Therapeutics Research Program at Winship.

Dr. Steuer received his medical degree from the New York University School of Medicine in 2009. He completed his postdoctoral training as a fellow in the department of hematology and medical oncology at the Emory University School of Medicine, where he was chief fellow in his final year.

He has been active in research including in clinical trial development, database analyses, and investigation of molecular biomarkers. He is interested in investigating the molecular biology and genomics of thoracic and head and neck tumors in order to be able to further the care of these patient populations. Additionally, he has taken an interest in utilizing national databases to perform clinical outcomes research, as well as further investigate rare forms of thoracic cancers.

Steuer's work has been published in many leading journals, such as Cancer, the Journal of Thoracic Oncology, and Lung Cancer, and has been presented at multiple international conferences.

Becky Upham, MA

Becky Upham

Author

Becky Upham has worked throughout the health and wellness world for over 25 years. She's been a race director, a team recruiter for the Leukemia and Lymphoma Society, a salesperson for a major pharmaceutical company, a blogger for Moogfest, a communications manager for Mission Health, a fitness instructor, and a health coach.

Upham majored in English at the University of North Carolina and has a master's in English writing from Hollins University.

Upham enjoys teaching cycling classes, running, reading fiction, and making playlists.

EDITORIAL SOURCES
Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined in our editorial policy. We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions.
Resources
  1. Systemic Mastocytosis. Mayo Clinic. November 20, 2020.
  2. Systemic Mastocytosis. Cleveland Clinic. October 28, 2022.
  3. SM-AHN. National Cancer Institute.
  4. Aggressive Systemic Mastocytosis. National Cancer Institute.
  5. Mast Cell Leukemia. National Cancer Institute.
  6. Khaddour K et al. Hematopoietic Stem Cell Transplantation. StatPearls. May 6, 2023.
  7. Reiter A et al. Efficacy of Avapritinib Versus Best Available Therapy in the Treatment of Advanced Systemic Mastocytosis. Leukemia. August 2022.
  8. Tremblay D et al. Management of Advanced Systemic Mastocytosis: Clinical Challenges. Journal of Blood Medicine. September 11, 2024.
  9. Pardanani A. Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management. American Journal of Hematology. July 2023.
  10. Buonomo A et al. Treatment of Indolent and Advanced Systemic Mastocytosis. Mediterranean Journal of Hematology and Infectious Diseases. May 1, 2022.
  11. Lübke J et al. Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries. Leukemia. April 2024.